Skip to main content
MedPath Trial logoMedPath TrialMedPath Trial Home
Clinical Trials/CTRI/2020/07/026878
CTRI/2020/07/026878Recruiting未知

Expansion of antimicrobial stewardship (AMSP) and infection control program (ICP) of ICMR in secondary care hospitals.

Indian Council of Medical Research0 sites0 target enrollmentStarted: TBDLast updated:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit

Trial Snapshot

Phase
未知
Status
Recruiting
Study OverviewEligibility CriteriaInvestigatorsRecords & IdentifiersSimilar Trials

Study Overview

Brief Summary

No summary available.

Study Design

Study Type
Interventional

Eligibility Criteria

Inclusion Criteria

  • •All the Health professionals from Nursing homes/ District hospitals who are willing to participate in the study.

Exclusion Criteria

  • •All the Health professionals from Nursing homes/ District hospitals who are not willing to participate in the stud

Investigators

Similar Trials

Active, not recruiting
Phase 1
Open-label study comparing 177Lu-PSMA-617 vs. a change of androgen receptor-directed therapy drugs in the treatment of mCRPC.PSMA-positive metastatic castration-resistant prostate cancerMedDRA version: 21.1Level: LLTClassification code 10076506Term: Castration-resistant prostate cancerSystem Organ Class: 100000004864
EUCTR2020-003969-19-CZovartis Pharma AG450
Active, not recruiting
Phase 1
Open-label study comparing 177Lu-PSMA-617 vs. a change of androgen receptor-directed therapy drugs in the treatment of mCRPC.
EUCTR2020-003969-19-SKovartis Pharma AG450
Active, not recruiting
Phase 1
Open-label study comparing 177Lu-PSMA-617 vs. a change of androgen receptor-directed therapy drugs in the treatment of mCRPC.PSMA-positive metastatic castration-resistant prostate cancerMedDRA version: 21.1Level: LLTClassification code 10076506Term: Castration-resistant prostate cancerSystem Organ Class: 100000004864
EUCTR2020-003969-19-NLovartis Pharma AG450
Recruiting
Unknown
Regional, Multi-center, Prospective, Single-arm, Real-World Observational study (SPADE)
CTRI/2023/09/058102Merck Pte Ltd
Recruiting
Phase 1
PSMAfore: A phase III, Open-label, Multi-Center, Randomized Study Comparing 177Lu-PSMA-617 vs. a Change of androgen receptor-directed therapy in the Treatment of Taxane Naïve Men with Progressive Metastatic Castrate Resistant Prostate CancerPSMA-positive metastatic castration-resistant prostate cancerMedDRA version: 21.1Level: LLTClassification code: 10076506Term: Castration-resistant prostate cancer Class: 10029104
CTIS2023-507772-50-00ovartis Pharma AG511